Anika Q3 revenue $41.5M (+3% YoY); raises FY2023 guidance to $164-166M

Anika Therapeutics, Inc.

2023-Q3 EPS reported -$1.34 revenue$123,691,000

Revenue $41.5M (+3% YoY); Joint Preservation & Restoration up 14% to $13.5M, OA Pain Mgmt up 2% to $24.9M.
Net loss ($6.6M), ($0.45)/share; adjusted net income $0.00/diluted share; includes $4.2M software charge.
Adjusted EBITDA $4.7M vs $4.1M; cash from ops $6.5M, cash $70.7M.
Raised FY2023 revenue guidance to $164-166M (from $159.5-163M), implying 5-6% growth.
FDA cleared Integrity Implant System (rotator cuff patch) and X-Twist biocomposite; launches Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Anika Therapeutics, Inc. updated its the third quarter ended September 30, 2023 guidance (raised).

Period: the third quarter ended September 30, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On November 2, 2023, Anika Therapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Anika Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-006678

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.